Results of the DEB-AMI Trial reported at TCT 2011

November 10, 2011

A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting stents (DES) found that the drug-eluting balloon group did not meet the primary endpoint of reduced late lumen loss. Results of the DEB-AMI (Drug Eluting Balloon in Acute Myocardial Infarction) trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Concerns regarding the safety of DES in ST-segment elevated acute myocardial infarctions (STEMI) continue to exist, including the risk of stent thrombosis. The use of drug-eluting balloons in angioplasty show potential as an alternative to treat STEMI.

In this randomized, international two-center, single-blinded three-arm study, patients were randomly assigned (ratio 1:1:1) to one of the following treatment groups: DEB plus BMS (n=50); BMS (n=50); or DES (n=49) after successful thrombus aspiration.

All patients underwent stenting with an identical stent platform. The primary endpoint was six- month angiographic late lumen loss. Secondary end points were six-month binary restenosis, stent malapposition and re-endothelialization assessed by OCT, assessed through acetylcholine testing, and major adverse cardiac events (MACE: death, , target vessel revascularization).

Late lumen loss at six months was as follows:

  • DEB+BMS: 0.64±0.56
  • BMS: 0.78±0.59
  • DES: 0.21±0.32
The rates of major adverse were as follows:
  • DEB+BMS: 10 (20.0%)
  • BMS: 12 (23.5%)
  • DES: 2 (4.1%)
"Results of the DEB-AMI trial indicate that drug-eluting stents induce more pronounced morphological changes (compared to drug-eluting balloons), resulting in superior angiographical and clinical outcomes with respect to bare and drug-eluting stents," said Pieter R. Stella, MD, PhD, the lead investigator of the trial. Dr. Stella is Director of the Heart Catheterization Laboratories and Director of Clinical Cardiovascular Research at the University Medical Centre Utrecht in The Netherlands.

Researchers noted however, that experience of the operators and discrepancies between the two trial sites may have impacted the findings.

Explore further: Lower rate of stent thrombosis found with second-generation drug-eluting stent than with bare metal stent

Related Stories

Results of the DESERT registry reported at TCT 2011

November 9, 2011

The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain types of patients, including smokers and those who are younger, are at ...

Recommended for you

What powers the pumping heart?

September 25, 2015

Researchers at the Ted Rogers Centre for Heart Research have uncovered a treasure trove of proteins, which hold answers about how our heart pumps—a phenomenon known as contractility.

Sticky gel helps stem cells heal rat hearts

September 24, 2015

A sticky, protein-rich gel created by Johns Hopkins researchers appears to help stem cells stay on or in rat hearts and restore their metabolism after transplantation, improving cardiac function after simulated heart attacks, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.